Loading organizations...
§ Private Profile · Beijing, Beijing, China
Medical technology company developing nucleic acid diagnostic technology, remote treatment products, genetic testing, and biomedicine.
Fanzhi Medicine, formally incorporated as Beijing Fanzhi Medical Technology Co., Ltd., is a biotechnology enterprise based in Beijing, China, that develops advanced nucleic acid diagnostic technology alongside specialized remote treatment products. The organization focuses its research and development efforts on the intersection of genetic testing and biomedicine, aiming to commercialize new diagnostic methodologies for the broader healthcare market. As part of its ongoing technology development strategy, the enterprise has successfully registered a portfolio of 22 patents to protect its proprietary medical innovations and diagnostic frameworks. While its primary research operations and corporate headquarters remain centralized in the Chinese capital, the firm has expanded its domestic footprint by establishing additional operational subsidiaries in the Tianjin and Jiangsu provinces. To address emerging demands within the molecular diagnostics industry, Fanzhi Medicine was officially established in 2016.
Fanzhi Medicine has raised $15.7M across 1 funding round.
Fanzhi Medicine has raised $15.7M in total across 1 funding round.
Fanzhi Medicine has raised $15.7M in total across 1 funding round.
Fanzhi Medicine's investors include GoldenSand Capital, Zhonghai Shengrong Capital.
Fanzhi Medicine has raised $15.7M across 1 funding round. Most recently, it raised $15.7M Series C in January 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 30, 2022 | $15.7M Series C | — | Goldensand Capital, Zhonghai Shengrong Capital | Announced |